Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | FABP1 | P07148 | 1/20 | 0.36 |
| ▸ | FABP6 | P51161 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23576570 | 0.72 | MAPT (0.32) | MAPT | |
| SCHEMBL11337049 | 0.71 | MEN1 (0.42) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL1008764 | 0.71 | MEN1 (0.45) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL6859755 | 0.66 | MEN1 (0.48) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL9663505 | 0.66 | SLC6A2 (0.55) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL2819853 | 0.66 | RAB9A (0.43) | RAB9AGAALMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL250513 | 0.64 | — | — | |
| SCHEMBL7484183 | 0.63 | MEN1 (0.45) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL6344808 | 0.63 | MEN1 (0.45) | MEN1KMT2AMAPK10GFERNPC1 | |
| SCHEMBL221242 | 0.63 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021130257-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | MEN1 4780/4885KMT2A 2467/4885MAPK10 3948/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | MEN1 4763/4885KMT2A 3223/4885MAPK10 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.